lasofoxifene has been researched along with Atrophy in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pinkerton, JV; Stanczyk, FZ | 1 |
Gennari, L | 1 |
3 review(s) available for lasofoxifene and Atrophy
Article | Year |
---|---|
Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Topics: Atrophy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Pelvic Organ Prolapse; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases | 2014 |
Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
Topics: Atrophy; Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vagina; Vaginal Diseases | 2009 |
Lasofoxifene: CP 336156, CP-336156.
Topics: Adult; Aged; Animals; Atrophy; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Musculoskeletal Diseases; Osteoporosis; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vaginal Diseases | 2005 |